Global X - Artificial Intelligence & Technology ETF
Limited financial coverage for AIQ.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The Global X Artificial Intelligence & Technology ETF (AIQ) aims to deliver investment outcomes that broadly align with the price appreciation and dividend returns of the Indxx Artificial Intelligence & Big Data Index, before accounting for the ETF's inherent fees and expenses.
- IPO
- 2018
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on AIQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.15B
- Div Yield
- 0.09%
- 52W High
- $70.26
- 52W Low
- $44.46
- 50D MA
- $62.65
- 200D MA
- $58.99
- Beta
- 1.56
- RSI (14)
- 24
- Avg Volume
- 1.34M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alliance Healthcare Services delivered solid Q1 growth in revenue, EBITDA, and cash flow, while reaffirming full-year 2017 guidance and highlighting a new oncology JV and merger process.· May 10, 2017
- Revenue rose 5% to $129.9 million, the ninth straight quarter of year-over-year growth.
- Adjusted EBITDA increased 7.9% to $32.8 million, outpacing revenue growth.
- The company reiterated full-year 2017 guidance: revenue of $529 million-$540 million and adjusted EBITDA of $135 million-$140 million.
- Radiology and oncology both benefited from business development, but oncology same-store volumes were weak early in the quarter before improving in March and April.
- Leverage improved to 4.0x and operating cash flow remained strong at $19.9 million.
Q1 2017 revenue was $129.9 million, up 5% or $6.2 million year over year. Adjusted EBITDA was $32.8 million, up 7.9% or $2.4 million year over year, and adjusted diluted EPS was $0.17 versus $0.04 last year; reported diluted EPS was a $0.06 loss per share versus a $0.11 loss per share a year ago. Revenue was driven by $7.6 million of contribution from business development, while organic growth was slightly negative after pricing and contract terminations. For the full year 2017, the company reaffirmed revenue guidance of $529 million-$540 million, adjusted EBITDA of $135 million-$140 million, total CapEx of $54 million-$70 million, maintenance CapEx of $30 million-$35 million, growth CapEx of $24 million-$35 million, free cash flow before growth CapEx of $50 million-$55 million, and free cash flow after growth CapEx of $19 million-$26 million.
Tom Tomlinson framed Q1 as evidence that 2017 is the year Alliance moves past its inflection point toward consistent earnings growth. He highlighted progress in oncology partnerships, including the new Golden, Colorado joint venture, and said the pipeline of radiology and oncology opportunities remains solid. His tone was constructive: he acknowledged early-quarter softness in same-store volumes, but emphasized the rebound in March and April and said operations protected earnings and margins.
Rhonda Longmore-Grund focused on the financial bridge behind the quarter. She cited $129.9 million of revenue, $32.8 million of adjusted EBITDA, 4.0x leverage, $19.9 million of operating cash flow, and debt of $565.5 million excluding deferred financing costs. She said business development added $3.9 million of adjusted EBITDA, corporate net spend increased due to headquarters relocation costs, audit fees, equity mix changes, and China investment, and free cash flow was $11.3 million before growth CapEx and $7.5 million after growth CapEx. She also reaffirmed full-year guidance and noted total CapEx of $22.2 million in the quarter, including $3.4 million of maintenance CapEx and $3.9 million of growth CapEx.
There was no substantive analyst Q&A in the transcript; the call appears to have ended without questions. The main management commentary instead centered on the merger with Tahoe, the new proxy and shareholder vote process, and the company’s reaffirmed outlook for 2017.
The quarter showed continued top-line momentum, with revenue up for the ninth consecutive quarter and adjusted EBITDA growing faster than sales. Management also pointed to strengthening same-store trends in March and April, a new oncology JV in Golden, Colorado, and a broader pipeline of partnership opportunities as signs that growth can continue.
Oncology same-store volumes were weak early in the quarter, with LINAC down 7.6% and SRS down 11.8%, and management called it the poorest same-store performance in recent years. The company also faces ongoing pricing pressure, contract terminations in legacy non-JV oncology sites, and higher corporate spend tied to headquarters relocation and international expansion.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- —
- Shares Outstanding
- 159.68M
- Float Shares
- —
of shares held by institutions
705 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pnc Financial Services Group, Inc. | 15.64M | ▼ 2.15M |
| Bank Of America Corp | 9.15M | ▲ 36.87K |
| Morgan Stanley | 5.46M | ▲ 147.74K |
| Lpl Financial LLC | 5.16M | ▼ 37.26K |
| Ubs Group AG | 4.86M | ▲ 420.45K |
| Neuberger Berman Group LLC | 2.14M | ▲ 715.45K |
| Northwestern Mutual Wealth Management Co | 1.68M | ▼ 22.20K |
| Wells Fargo & Company/Mn | 1.65M | ▼ 112.47K |
| Jpmorgan Chase & Co | 1.53M | ▲ 9.84K |
| Hancock Prospecting Pty Ltd | 1.49M | 0 |
| Raymond James Financial Inc | 1.47M | ▲ 134.35K |
| Royal Bank Of Canada | 1.44M | ▲ 10.43K |
Held by 2 ETFs
Biggest fund positions in AIQ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 21, 17 | Bartos Scott A. | sell | 39,525 |
| Dec 31, 16 | Bartos Scott A. | other | 14,917 |
| Dec 31, 15 | Bartos Scott A. | other | 15,812 |
| Dec 31, 14 | Bartos Scott A | other | 6,602 |
| Dec 31, 13 | Bartos Scott A | other | 1,668 |
| Dec 31, 12 | Bartos Scott A | other | 526 |
| Dec 31, 12 | Bartos Scott A | other | 0 |
| Nov 1, 10 | OCM Principal Opportunities Fund IV, LP | buy | 342,101 |
| Nov 1, 10 | OCM Principal Opportunities Fund IV, LP | buy | 25,307 |
| Nov 1, 10 | OCM Principal Opportunities Fund IV, LP | buy | 5,061 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AIQ coverage
Recent articles, reports, and earnings notes.

What to Watch as Tidal Trust V Hits the Public Market
Tidal Trust V (NYSE: AIBN) is expected to list on 2026-10-20, but the price range has not been disclosed. This is an ETF trust listing, not a traditional operating-company IPO, so the key question is whether investors want AI compute exposure packaged through derivatives. Bull case: a timely thematic launch; bear case: the strategy depends on a still-developing market with liquidity and pricing risk.

MicroSectors 3A Long Artificial Intelligence (AI) ETN IPO Preview: 3x AI Leverage
MicroSectors 3A Long Artificial Intelligence (AI) ETN is expected to list on the NYSE on 2026-06-02, but the price range has not been disclosed. The setup is straightforward: traders get 3x long exposure to an AI index, while shareholders should watch leverage, concentration, and daily-reset risk.
Want a deeper read on AIQ?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Why Are Hyperscaler Stocks Still Struggling After Strong Q3 Earnings?
benzinga.com · Nov 4
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
247wallst.com · Nov 2
Nvidia & AMD Bet $4B on Meta: Grab These ETFs to Own the AI Ecosystem
zacks.com · Oct 28
Hedge Hyperscaler Volatility With AI Infrastructure Stocks
benzinga.com · Oct 22
Global X ETFs Launches New Website and Largest Brand Campaign as Investors Embrace Innovation
businesswire.com · Oct 19
Afraid of a Stock Market Crash? 4 Great ETFs to Buy Regardless.
fool.com · Oct 12
Thematic ETFs Have Exploded in 2026: See the Standouts
etftrends.com · Oct 5
A Guide to AI ETF Investment
zacks.com · Oct 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.